Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20443236 | 0.84 | IRAK4 (0.31) | — | |
| SCHEMBL20443037 | 0.79 | — | — | |
| SCHEMBL20759578 | 0.76 | — | — | |
| SCHEMBL20930355 | 0.74 | ABL1 (0.35) | — | |
| SCHEMBL24843677 | 0.74 | PDE2A (0.35) | — | |
| SCHEMBL21361794 | 0.74 | GSK3B (0.33) | — | |
| SCHEMBL21354067 | 0.73 | L3MBTL1 (0.41) | — | |
| SCHEMBL16156519 | 0.70 | LPL (0.41) | SNCA | |
| SCHEMBL20651743 | 0.69 | — | — | |
| SCHEMBL22759057 | 0.69 | EGFR (0.35) | SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765008-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-06-07 | — | — | EP | disclosed |
| US-10894052-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-19 | — | — | US | disclosed |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894052-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | SNCA 3515/4885 |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | SNCA 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.